You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK):東阿阿膠預計年度淨利4.28億至4.75億元

格隆匯1月28日丨華潤醫藥(03320.HK)發佈公吿,2022年1月27日,東阿阿膠(000423.SZ)公佈其截至2021年12月31日止年度業績預吿,該年度歸屬於東阿阿膠股東的淨利潤預計約人民幣4.275億元至4.748億元(上年同期:淨盈利約人民幣4328.93萬元)、扣除非經常性損益後淨利潤預計約人民幣3.451億元至3.832億元(上年同期:淨虧損約人民幣3946.21萬元)、基本每股收益預計約人民幣0.66元╱股至約人民幣0.74元╱股(上年同期:盈利約人民幣0.07元╱股)。

公吿表示,本次業績變動的主要原因如下:1.東阿阿膠堅持以消費者為中心,專注顧客增長與保留,加快推進產品創新,強化科研成果轉化,不斷釋放品牌生產力,實現穩定良性增長。2.未來,東阿阿膠將積極響應國家推進中醫藥傳承創新發展的號召,堅持以成為“中式滋補健康領域中消費者最為信賴的大健康企業”為指引,以顧客需求為導向,加快數字轉型和商業模式創新;深入推進“價值重塑、業務重塑、組織重塑、精神重塑”,鞏固核心產品市場領導地位,延伸現有品牌品類,圍繞市場與顧客需求提供解決方案,提升數位化轉型組織能力,推進東阿阿膠高品質發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account